← Return to Good news, Bensocatib Trials Continue for Bronchieactasis

Discussion

Good news, Bensocatib Trials Continue for Bronchieactasis

MAC & Bronchiectasis | Last Active: Aug 20 1:10pm | Replies (24)
Comment receiving replies
@becleartoday

Brensocatib--
Insmed said its experimental drug to treat a type of chronic lung disease helped significantly reduce respiratory symptoms such as chronic cough in a late-stage study.
The drug candidate, brensocatib, is being developed to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung condition where the walls of the airways are widened due to inflammation and infection.
The company said it plans to file a marketing application for brensocatib with the U.S. Food and Drug Administration in the fourth quarter of this year, and it expects to launch the drug in mid-2025.

Jump to this post

Replies to "Brensocatib-- Insmed said its experimental drug to treat a type of chronic lung disease helped significantly..."
scoop | @scoop | May 28 4:12pm

Thanks for posting! Curious how you read this? Does "late stage" seem less than what they set out to do?

VIEW AND REPLY
fdixon63 | @fdixon63 | May 29 7:44am

Hi becleartoday. OK, my need for clarification is, what is topline results? Thanks.

VIEW AND REPLY
becleartoday | @becleartoday | May 29 7:49am

Topline results in a clinical trial refer to the high-level summary of the key findings from the trial. They typically include the primary efficacy and safety data points, without providing the full detailed results or analysis.

VIEW AND REPLY
Justin McClanahan, Moderator | @JustinMcClanahan | May 29 10:41am

Hello @becleartoday - I merged your discussion with @harrynsc's discussion on the same topic - https://connect.mayoclinic.org/discussion/good-news-for-bronchiectasis/ so all of the members talking about this study could be in one place.

Like @sueinmn mentioned, the article linked in this discussion is a stock report. Have you been able to track down the study data link that you are referring to? I found one article, but it is from 2020, https://www.nejm.org/doi/full/10.1056/NEJMoa2021713.

VIEW AND REPLY